CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Status Completed

Clinical Trial Summary

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.

Clinical Trial Description

This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell leukemia. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell leukemia. ;

Study Design

Related Conditions & MeSH terms

B-cell Leukemia
Leukemia
Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trial Details

NCT number	NCT04260945
Study type	Interventional
Source	Hebei Yanda Ludaopei Hospital
Contact
Status	Completed
Phase	Phase 1
Start date	March 10, 2020
Completion date	February 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03068416` - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy	Phase 2
Recruiting	`NCT05487651` - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies	Phase 1
Withdrawn	`NCT05570188` - Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT03448393` - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Phase 1
Recruiting	`NCT02963038` - CAR T Cells for Refractory B Cell Malignancy	Phase 1/Phase 2
Completed	`NCT00230282` - Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia	Phase 2
Recruiting	`NCT04016129` - CAR-T Immunotherapy Targeting CD19- ALL	Phase 1/Phase 2
Not yet recruiting	`NCT06208735` - CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies	Phase 1
Recruiting	`NCT05932173` - A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies	Phase 1/Phase 2
Completed	`NCT00849654` - Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma	Phase 1
Withdrawn	`NCT03098355` - Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies	Phase 1/Phase 2
Recruiting	`NCT05442515` - CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Phase 1/Phase 2